Compare MERC & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MERC | CALC |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 7.6M |
| IPO Year | 2005 | 2020 |
| Metric | MERC | CALC |
|---|---|---|
| Price | $0.25 | $1.35 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $0.13 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 25.4M | 78.7K |
| Earning Date | 11-05-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,169,145,000.00 | N/A |
| Revenue This Year | $0.85 | N/A |
| Revenue Next Year | $11.46 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.50 | N/A |
| 52 Week Low | $0.12 | $0.44 |
| 52 Week High | $2.85 | $72.00 |
| Indicator | MERC | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 56.93 | 44.38 |
| Support Level | $0.14 | $1.00 |
| Resistance Level | $0.41 | $1.84 |
| Average True Range (ATR) | 0.04 | 0.21 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 52.79 | 40.24 |
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the maximum of revenue is generated from the China. The majority of the revenue is generated from the Pulp segment.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.